Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo

Blood

Volumn 86, Issue 5, 1995, Pages 2008-2013

  Shalev, Oded ^b   Repka, Tanya ^b   Goldfarb, Ada ^b   Grinberg, Leonid ^b   Abrahamov, Ayala ^b   Olivieri, Nancy F ^b   Rachmilewitz, Eliezer A ^b   Hebbel, Robert P ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; MALONALDEHYDE;

ARTICLE; CELL MEMBRANE PERMEABILITY; DOSE TIME EFFECT RELATION; ERYTHROCYTE MEMBRANE; HEMOSIDEROSIS; HUMAN; HUMAN CELL; IRON CHELATION; IRON OVERLOAD; IRON STORAGE; LIPID PEROXIDATION; OXIDATION; PRIORITY JOURNAL; SICKLE CELL; STOICHIOMETRY; THALASSEMIA;

EID: 0029097965     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v86.5.2008.bloodjournal8652008     Document Type: Article

References (28)

1. Brittenham GM: The red cell cycle, in Brock J, Halliday J, Pippard M, Powell L (eds): Iron Metabolism in Health and Disease. Philadelphia, PA, Saunders, 1994, p 31
2. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 331:574, 1994
3. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567, 1994
4. Brittenham GM: Development of iron-chelating agents for clinical use. Blood 80:569, 1992
5. Hoffbrand AV: Prospects for oral iron chelation therapy. J Lab Clin Med 123:492, 1994
6. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ: Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations. Br J Haematol 76:301, 1990
7. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G: Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332:918, 1995
8. Hershko C: Development of oral iron chelator L1. Lancet 341:1088, 1993 (letter)
9. Kontoghiorghes GJ: Design, properties, and effective use of the oral chelator L1 and other α-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia. Ann NY Acad Sci 612:339, 1990
10. Kontoghiorghes GJ: Structure/red blood cell permeability. Activity of iron (III) chelator complexes. Inorg Chim Acta 151:101, 1988
11. Repka T, Shalev O, Reddy R, Yuan J, Abrahamov A, Rachmilewitz EA, Low PS, Hebbel RP: Nonrandom association of free iron with membranes of sickle and β-thalassemic erythrocytes. Blood 82:3204, 1993
12. Kuross SA, Hebbel RP: Nonheme iron in sickle erythrocyte membranes: Association with phospholipids and potential role in lipid peroxidation. Blood 72:1278, 1988
13. Hebbel RP: Membrane-associated iron, in Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds): Sickle Cell Disease: Scientific Principles and Clinical Practice. New York, NY, Raven, 1994, p 163
14. Shinar E, Rachmilewitz EA: Haemoglobinopathies and red cell membrane function. Baillieres Clin Haematol 6:357, 1993
15. Kuross SA, Rank BH, Hebbel RP: Excess heme in sickle erythrocyte inside-out membranes. Possible role in thiol oxidation. Blood 71:876, 1988
16. Aust SD: Lipid peroxidation, in Greenwald RA (ed): CRC Handbook of Methods for Oxygen Research. Boca Raton, FL, CRC, 1985, p 203
17. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L: Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 48:255, 1990
18. Allain P, Mauras Y, Chaleil D, Simon P, Ang KS, Cam G, Le Mignon L, Simon M: Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis. Br J Clin Pharmacol 32:207, 1987
19. Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF: Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 83:2329, 1994
20. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT: Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 82:460, 1992
21. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP: L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol 76:550, 1990
22. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P: Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 76:295, 1990
23. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ: Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 80:593, 1992
24. Hebbel RP: Beyond hemoglobin polymerization: The red blood cell membrane and sickle disease pathophysiology. Blood 77:214, 1991
25. Repka T, Hebbel RP: Hydroxyl radical formation by sickle erythrocyte membranes: Role of pathologic iron deposits and cytoplasmic reducing agents. Blood 78:2753, 1991
26. Rachmilewitz EA, Lubin BH, Shohet SB: Lipid membrane peroxidation in β-thalassemia major. Blood 47:495, 1976
27. Sadrzadeh SMH, Nanji AA, Price PL: The oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one reduces hepatic-free iron, lipid peroxidation and fat accumulation in chronically ethanol-fed rats. J Pharmacol Exp Ther 269:632, 1994
28. Eguchi LA, Saltman P: The aerobic reduction of Fe(III) complexes by hemoglobin and myoglobin. J Biol Chem 259:14337, 1984